Foghorn Therapeutics Inc. (NASDAQ:FHTX) People
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Noubar Afeyan Other companies: Generate Biomedicines, Inc. (Chair of the Board · Since at least Feb 26, 2026); Moderna, Inc. (Director · Since at least Dec 7, 2018); BG Medicine Inc (Director · Since at least Feb 3, 2011); Omega Therapeutics Inc (Director · Jul 29, 2021 – Jun 7, 2023 · Past); Kaleido Biosciences, Inc. (Director · Feb 27, 2019 – Mar 4, 2019 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – May 12, 2022 · Past); Evelo Biosciences, Inc. (Director · May 8, 2018 – Jun 12, 2019 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 21, 2016 · Past); Seres Therapeutics, Inc. (Director · Jun 25, 2015 – Jun 18, 2019 · Past); Eleven Biotherapeutics Inc (Director · Feb 5, 2014 – Mar 20, 2014 · Past); BIND Therapeutics Inc (Director · Sep 19, 2013 – Sep 25, 2013 · Past); Color Kinetics Inc (Director · Jan 3, 2006 – Aug 24, 2007 · Past); Agenus Inc. (Director · Jan 13, 2005 – Jun 7, 2007 · Past) | Director · Since at least Jan 13, 2026 |
| Adam Koppel Other companies: Kailera Therapeutics, Inc. (Partner, Bain Capital Life Sciences · Since at least Apr 16, 2026); Cerevel Therapeutics Holdings Inc (Director · Oct 27, 2020 – Aug 1, 2024 · Past); BCLS Acquisition Corp (Director · Oct 21, 2020 – Oct 26, 2020 · Past); Replimune Group, Inc. (Director · Jul 24, 2018 – Jul 24, 2018 · Past); Aptinyx Inc (Director · Jun 20, 2018 – May 26, 2022 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Dicerna Pharmaceuticals Inc (Director · Apr 11, 2017 – Dec 28, 2021 · Past); Trevena, Inc. (Director · Sep 17, 2014 – May 16, 2018 · Past); Biogen Inc. (EVP, Strategy and Bus. Dev. · May 15, 2014 – Jun 6, 2016 · Past); PTC Therapeutics, Inc. (Director · Jun 19, 2013 – Jan 3, 2017 · Past) | Director · Oct 22, 2020 – Dec 29, 2024 · Past |
| Douglas G Cole Other companies: Sana Biotechnology, Inc. (Director · Feb 3, 2021 – Jun 6, 2024 · Past); Sigilon Therapeutics Inc (Director · Dec 3, 2020 – Aug 11, 2023 · Past); Denali Therapeutics Inc. (Director · Dec 7, 2017 – Jun 1, 2023 · Past); Quanterix Corporation (Director · Dec 6, 2017 – Jan 2, 2019 · Past); Editas Medicine, Inc. (Director · Feb 2, 2016 – Aug 17, 2017 · Past); Agios Pharmaceuticals, Inc. (Director · Jul 23, 2013 – Aug 10, 2016 · Past); Receptos Inc (Director · May 8, 2013 – Jul 17, 2013 · Past); Tetraphase Pharmaceuticals Inc (Director · Mar 19, 2013 – Mar 25, 2013 · Past); AVEO Pharmaceuticals Inc (Director · Mar 11, 2010 – May 12, 2011 · Past) | Director · Since at least Oct 22, 2020 |
| David Schenkein Other companies: Regeneron Pharmaceuticals, Inc. (Director · Since at least Sep 8, 2023); Prime Medicine, Inc. (Board Member · Since at least Oct 19, 2022); Denali Therapeutics Inc. (Director · Since at least Dec 7, 2017); Foundation Medicine Inc (Director · Sep 24, 2013 – Jun 16, 2016 · Past); Agios Pharmaceuticals, Inc. (Director · Jul 23, 2013 – Jun 20, 2024 · Past); Bluebird bio Inc (Director · Jun 18, 2013 – Jun 18, 2020 · Past) | General Partner, Co-leader, Agios · Until Apr 13, 2026 · Past |
| Lynne Parshall Other companies: Cytokinetics, Incorporated (Director · Since at least Feb 7, 2013); Ionis Pharmaceuticals, Inc. (Director · Since at least Jan 3, 2006); Akcea Therapeutics Inc (Director · Jul 13, 2017 – Oct 12, 2020 · Past); Regulus Therapeutics Inc (Director · Oct 4, 2012 – Nov 3, 2014 · Past); Cardiodynamics International Corp (Director · Jul 20, 2006 – Aug 14, 2009 · Past) | Director, Ionis Pharmaceuticals · Since at least Aug 16, 2022 |
| Ian Smith Other companies: Odyssey Therapeutics, Inc. (Director · Since at least May 7, 2026); Stoke Therapeutics, Inc. (Chief Executive Officer, Director · Since at least Sep 19, 2023); Solid Biosciences Inc. (Chairman of the Board · Since at least Dec 10, 2020) | Director · Since at least Apr 27, 2021 |
| Kristian Humer Other companies: 4D Molecular Therapeutics, Inc. (Chief Financial Officer · Since at least Dec 9, 2025); Sensei Biotherapeutics, Inc. (Director · Jul 30, 2021 – May 21, 2025 · Past); Viridian Therapeutics, Inc. (CFO and CBO · Jul 26, 2021 – Feb 8, 2023 · Past) | Chief Financial Officer · Since at least Apr 16, 2024 |
| Ryan Maynard Other companies: Iovance Biotherapeutics, Inc. (Director · Since at least Feb 16, 2015); Tvardi Therapeutics, Inc. (CHIEF FINANCIAL OFFICER · Sep 12, 2022 – Feb 8, 2024 · Past); Rigel Pharmaceuticals, Inc. (EVP & CFO · May 27, 2010 – Nov 3, 2017 · Past) | Chief Financial Officer · Since at least Feb 23, 2026 |
| Stuart Duty Other companies: Milestone Pharmaceuticals Inc. (Independent Non-Executive Director · Since at least Jul 15, 2024); EyePoint, Inc. (Board Member · Since at least Oct 16, 2023); Achieve Life Sciences, Inc. (Director · Since at least Mar 29, 2023) | Director · Since at least May 1, 2025 |
| Jose Baselga Other companies: Bristol-Myers Squibb Company (Director · Mar 1, 2018 – Sep 30, 2018 · Past); Varian Medical Systems Inc (Director · Mar 1, 2017 – Feb 9, 2018 · Past) | Director · Oct 22, 2020 – Oct 22, 2020 · Past |
| Neil Gallagher Other companies: Zymeworks Inc. (Director · Apr 2, 2024 – Dec 10, 2024 · Past); Syndax Pharmaceuticals, Inc. (President, Head of R&D · Feb 7, 2024 – Feb 10, 2025 · Past) | Most recently President, Head of Research & Development, Syndax Pharmaceuticals · Since at least May 1, 2025 |
| Simba Gill Other companies: Serina Therapeutics, Inc. (Director · Since at least Apr 12, 2024); Evelo Biosciences, Inc. (President & CEO, Director · May 8, 2018 – Nov 7, 2023 · Past) | Executive Chairman, Serina Therapeutics and Sensorium Therapeutics · Since at least Oct 22, 2020 |
| Thomas J Lynch Jr Other companies: Natera, Inc. (Director · Since at least Jun 2, 2026); Bristol-Myers Squibb Company (EVP & Chief Scientific Officer · Dec 12, 2017 – Apr 3, 2019 · Past) | Director · Since at least Oct 27, 2022 |
| Alfonso Quintás-Cardama Other companies: Tcr2 Therapeutics Inc (Chief Medical Officer · Feb 13, 2019 – Jun 1, 2023 · Past) | Chief Medical Officer · Since at least Sep 11, 2023 |
| Allan Reine Other companies: Prime Medicine, Inc. (Chief Executive Officer, Director · Since at least Jan 17, 2024) | Chief Financial Officer · Jan 26, 2023 – Jan 16, 2024 · Past |
| Michael Mendelsohn Other companies: Cyclerion Therapeutics, Inc. (Director · Apr 1, 2019 – Jun 14, 2022 · Past) | Founder, Board Director, & Chief Strategy Officer, Cardurion Pharmaceuticals · Since at least Oct 22, 2020 |
| Samuel Agresta Other companies: OnKure Therapeutics, Inc. (Chief Medical Officer · Since at least Oct 4, 2024) | Chief Medical Officer · Oct 22, 2020 – Sep 11, 2023 · Past |
| Scott Biller Other companies: Agios Pharmaceuticals, Inc. (Chief Scientific Officer · Jul 23, 2013 – Jun 11, 2019 · Past) | Executive Venture Partner, Google Ventures (GV) · Since at least Oct 22, 2020 |
| Adrian Gottschalk | President & CEO · Since at least Oct 22, 2020 |
| Alena Reva | VP, Total Rewards & People Operations · Since at least Nov 5, 2026 |
| Andrew Germain | VP, Legal · Since at least Nov 5, 2026 |
| Anna Rivkin | Chief Business Officer · Since at least Sep 3, 2024 |
| Carlos Costa | Chief People Officer · Since at least Jan 24, 2024 |
| Charles Sawyers | Investigator, Howard Hughes Medical Institute Marie-Josée and Henry Kravis Chair in Human Oncology and Pathogenesis and Chairman, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Canc · Since at least Nov 5, 2026 |
| Cigall Kadoch | Scientific Advisor to the Board of Directors; Founder, Foghorn Therapeutics · Since at least Oct 22, 2020 |
| Dan Dinu | VP, Information Technology · Since at least Nov 4, 2026 |
| Danette Daniels | VP, Protein Degrader Platform · Since at least Apr 9, 2026 |
| Doug Cole | Founder, Foghorn Therapeutics; Managing Partner, Flagship Pioneering · Since at least Nov 4, 2026 |
| Fanny Cavalie | Chief Strategy/Bus Ops Officer · Feb 14, 2022 – Jun 21, 2024 · Past |
| Gerald Crabtree | Founder, Foghorn Therapeutics David Korn Professor, Stanford University Medical School Investigator, Howard Hughes Medical Institute · Since at least Nov 5, 2026 |
| Gromek Smolen | VP, Biology · Since at least Apr 9, 2026 |
| Karin Hellsvik | Chief of Staff to the CEO, VP, Head of Corporate Affairs, Investor Relations, Operations · Since at least Nov 3, 2026 |
| Kevin Wilson | VP, Chemistry · Since at least Nov 5, 2026 |
| Michael Garcia-Webb | VP, Program Executive, Chief of Staff Research · Since at least Nov 5, 2026 |
| Michael LaCascia | Chief Legal Officer · Since at least Nov 9, 2020 |
| Saurabh Sewak | VP, New Products & Commercial Strategy · Since at least Nov 5, 2026 |
| Steven Bellon | Chief Scientific Officer · Since at least Apr 9, 2026 |
| Steven F Bellon | Chief Scientific Officer · Since at least Oct 22, 2020 |
| Tom Lynch | President & Director, Fred Hutchinson Cancer Center · Since at least Nov 4, 2026 |